Market Overview

XTL Biopharma Buys Stake in Proteologics from Teva

Related TEVA
US Stock Futures Edge Higher Ahead Of Economic Data
Teva Announces Proposed Public Offerings Of Amer Depositary Shrs And Mandatory Convertible Preferred Shares In Connection With Pending Acquisition Of Actavis Generics
Premarket Biotech Digest: FibroGen's Gains, Anavex Data, Geron Rallies (Seeking Alpha)

XTL Biopharmaceuticals Ltd. announced on November 21^st that it has acquired 4,620,356 shares, of Proteologics Ltd., from Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) in consideration for an amount of approximately NIS 6.5 million, which represents an amount of NIS 1.405 per Share (approximately 22% premium). The Shares represent all of Teva's shares in Proteologics and represent approximately 31.35% of Proteologics issued and outstanding share capital.

Posted-In: News Asset Sales


Related Articles (TEVA)

Get Benzinga's Newsletters